Springer Healthcare Announces Agreement With ASCO®

Springer Healthcare, part of Springer Science+Business Media, has signed an extensive three-year reprints and sales agreement effective 1 January 2012 with the American Society of Clinical Oncology® (ASCO), the world's leading professional organization representing physicians who care for people with cancer.

"Springer Healthcare is a leader in global licensing sales and has a track record of producing materials that are of high quality and value," said Dr. Allen Lichter, Chief Executive Officer of ASCO. "We are looking forward to working with Springer Healthcare to further the reach of many of ASCO's educational resources, including our flagship journal, the Journal of Clinical Oncology and our practice management journal, the Journal of Oncology Practice."

Springer Healthcare will be the exclusive supplier of reprints from articles published in ASCO's Journal of Clinical Oncology and Journal of Oncology Practice for North and South America, most of Europe, India, and other territories. In addition, Springer Healthcare will be the exclusive representative for licensing of other ASCO educational resources including the ASCO Annual Meeting abstracts and Educational Book, Virtual Meeting content, symposia proceedings, patient materials, and ASCO University® - the Society's online learning environment.

Steve Entwistle, Vice President of Springer Healthcare, commented, "We are honored to be appointed by ASCO to represent their journal reprints business as well as their other prestigious content. We value our relationship with ASCO, and we appreciate the confidence that they are showing in us."

About Springer Healthcare
Springer Healthcare is a leading publisher of medical educational products and forms part of Springer Science+Business Media. Springer Healthcare has undergone significant growth in the past decade and has expanded rapidly, with global reach into all international markets and more than 150 employees worldwide. Springer Healthcare's focus is on meeting the communication and publishing needs of the international healthcare communities, with a growing portfolio of products, including MedWire News, strategic consultancy, event management, eBusiness products and services, as well as print and digital medical publishing.

About Springer Science+Business Media
Springer Science+Business Media is a leading global scientific publisher, delivering quality content through innovative information products and services. The company is also a trusted provider of local-language professional publications in Europe, especially in Germany and the Netherlands. In the science, technology and medicine (STM) sector, the group publishes about 2,000 journals and more than 7,000 new books per year, as well as the largest STM eBook Collection worldwide. Springer has operations in about 20 countries in Europe, the USA, and Asia, and has more than 5,500 employees. In 2010, it generated annual sales of approximately EUR 866 million.

Most Popular Now

Pfizer receives positive FDA Advisory Committee vo…

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that avail...

Engineered bacteria find tumors, then alert the au…

Combining discoveries in cancer immunology with sophisticated genetic engineering, Columbia University researchers have created a sort of "bacterial suicide squad" that ...

First nasal monoclonal antibody treatment for COVI…

A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, tested the nasal administration of the ...

US FDA Advisory Committee votes to support effecti…

GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the avail...

"Semantic similarity" leads to novel dru…

The words that researchers use to describe their results can be harnessed to discover potential new treatments for Parkinson's disease, according to a new study published...

Tumour cells' response to chemotherapy is driven b…

Cancer cells have an innate randomness in their ability to respond to chemotherapy, which is another tool in their arsenal of resisting treatment, new research led by the...

Pfizer invests $43 billion to battle cancer

Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a...

Pfizer's ZAVZPRET™ (zavegepant) migraine nasal spr…

Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptid...

Gene and cell therapies to combat pancreatic cance…

Pancreatic cancer is an incurable form of cancer, and gene therapies are currently in clinical testing to treat this deadly disease. A comprehensive review of the gene an...

Scientists reveal a potential new approach to trea…

Scientists at the National Institutes of Health and Massachusetts General Hospital in Boston have uncovered a potential new approach against liver cancer that could lead ...

Normalizing tumor blood vessels may improve immuno…

A type of immune therapy called chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of multiple types of blood cancers but has shown limited e...

Digital twin opens way to effective treatment of i…

Inflammatory diseases like rheumatoid arthritis have complex disease mechanisms that can differ from patient to patient with the same diagnosis. This means that currently...